TY - JOUR
T1 - Development and Pharmacological assessment of dehydrozingerone gel formulation on imiquimod-induced psoriasis in mice
AU - Hari, Gangadhar
AU - Prabhu, Anusha
AU - Kalakota, Chaitanyamayee
AU - Johnson, Jeslin
AU - Mansoor, Kufaila
AU - Shenoy, Rekha R.
AU - Pai, Karkala Sreedhara Ranganath
AU - Nandakumar, Krishnadas
N1 - Funding Information:
This project was funded by Manipal College of Pharmaceutical Sciences, MAHE, Manipal, India.
Funding Information:
Study was supported by the Department of Pharmacology, Manipal College of Pharmaceutical Sciences, Manipal. This project would not have been successful without timely guidance and support of Ms. Neesha J Dargad, Mr Manas Kinra, Mr Jayant Singh, Ms. Runali Sankhe, Research Scholars M.Pharm students and Research Scholars of Manipal College of Pharmaceutical Sciences, Manipal.
Publisher Copyright:
© RJPT All right reserved.
PY - 2022/10
Y1 - 2022/10
N2 - Psoriasis is a chronic inflammatory autoimmune skin disorder, generally due to the interaction between genetic, environmental and immune factors. It is mainly associated with HLA locus (HLA-C), particularly with HLA-Cw* 0602 allele. The stimulation of T-cell induces hyper-proliferation of keratinocytes, which results in psoriatic lesions. Psoriatic patients are usually treated with medications that block TNF-α function. Complexities in the pathogenesis of psoriasis have been a challenge to develop an effective treatment regimen. Thus, studies are still underway for exploring drugs to treat psoriasis. Researchers have reported the antioxidant, antibacterial and anti-inflammatory properties of the structural half analogue of curcumin, dehydrozingerone (DHZ). Pre-clinical studies have reported the wound healing and anti-inflammatory properties of this compound. DHZ is also capable of blocking TNF alpha, which is one of the early cytokines implicated in psoriasis. Therefore, the current study has been proposed to explore the effect of DHZ to reduce psoriatic like lesions in imiquimod-induced psoriasis in mice. Upon the development of psoriatic like lesions, clinical scoring for scaling and erythema was taken on a scale of 0-4. DHZ has shown a significant reduction of scaling in comparison to the disease control, denoting the effectiveness of the test drug.
AB - Psoriasis is a chronic inflammatory autoimmune skin disorder, generally due to the interaction between genetic, environmental and immune factors. It is mainly associated with HLA locus (HLA-C), particularly with HLA-Cw* 0602 allele. The stimulation of T-cell induces hyper-proliferation of keratinocytes, which results in psoriatic lesions. Psoriatic patients are usually treated with medications that block TNF-α function. Complexities in the pathogenesis of psoriasis have been a challenge to develop an effective treatment regimen. Thus, studies are still underway for exploring drugs to treat psoriasis. Researchers have reported the antioxidant, antibacterial and anti-inflammatory properties of the structural half analogue of curcumin, dehydrozingerone (DHZ). Pre-clinical studies have reported the wound healing and anti-inflammatory properties of this compound. DHZ is also capable of blocking TNF alpha, which is one of the early cytokines implicated in psoriasis. Therefore, the current study has been proposed to explore the effect of DHZ to reduce psoriatic like lesions in imiquimod-induced psoriasis in mice. Upon the development of psoriatic like lesions, clinical scoring for scaling and erythema was taken on a scale of 0-4. DHZ has shown a significant reduction of scaling in comparison to the disease control, denoting the effectiveness of the test drug.
UR - http://www.scopus.com/inward/record.url?scp=85144542862&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85144542862&partnerID=8YFLogxK
U2 - 10.52711/0974-360X.2022.00749
DO - 10.52711/0974-360X.2022.00749
M3 - Article
AN - SCOPUS:85144542862
VL - 15
SP - 4469
EP - 4472
JO - Research Journal of Pharmacy and Technology
JF - Research Journal of Pharmacy and Technology
SN - 0974-3618
IS - 10
ER -